Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 1;16(9):e68401.
doi: 10.7759/cureus.68401. eCollection 2024 Sep.

Botulinum Toxin for the Treatment of Postmenopausal Craniofacial Hyperhidrosis

Bailey Patrick  1 , Anne-Taylor Beck  1 , Benjamin W Casterline  1 , Kari L Martin  1
Affiliations
Case Reports

Botulinum Toxin for the Treatment of Postmenopausal Craniofacial Hyperhidrosis

Bailey Patrick et al. Cureus. .

Abstract

Postmenopausal craniofacial hyperhidrosis describes a unique subset of primary focal hyperhidrosis in menopausal woman. This condition can be challenging to treat and may require multiple treatment modalities before patients express satisfaction with the results. Current treatment options for craniofacial hyperhidrosis include oral antimuscarinic agents, topical aluminum chloride powder, and botulinum toxin injections. We present the case of a 68-year-old female with craniofacial hyperhidrosis who did not respond to topical agents and did not tolerate an oral antimuscarinic agent. The patient was successfully treated with 100 units of onabotulinum toxin A along the forehead, frontal hairline, and periauricular scalp and reported significant improvement in symptoms and quality of life as a result. We review the literature describing targeted intradermal injection of botulinum neurotoxin as an alternative to medical therapy for craniofacial hyperhidrosis.

Keywords: adult dermatology; botulinum toxin (botox) treatment; craniofacial hyperhidrosis; hyperhidrosis; postmenopause.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Injection sites for the patient around the upper forehead and frontal hairline, temporal hairline, and around the auricle to the mastoid.
Created with BioRender from the injection sites of the patient at the office visit.
See this image and copyright information in PMC

References

    1. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. Hornberger J, Grimes K, Naumann M, et al. J Am Acad Dermatol. 2004;51:274–286. - PubMed
    1. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY. J Am Acad Dermatol. 2007;56:604–611. - PubMed
    1. Botulinum toxin A and B for palmoplantar hyperhidrosis. Eilertsen T, Kvammen BØ, Grimstad Ø. Dermatol Ther (Heidelb) 2024;14:805–811. - PMC - PubMed
    1. Postmenopausal craniofacial hyperhidrosis. Eustace K, Wilson NJ. Clin Exp Dermatol. 2018;43:180–182. - PubMed
    1. Postmenopausal craniofacial hyperhidrosis. Hanna-Bashara L, Wilson N. Clin Derm Other Cutan Disorders. 2013;68:4.

Publication types

LinkOut - more resources